Trials / Completed
CompletedNCT00518453
Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008
A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Ph.Eur, Formulation 2007-2008, When Administered to Non-Elderly Adult and Elderly Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 129 (actual)
- Sponsor
- Novartis Vaccines · Industry
- Sex
- All
- Age
- 18 Years – 84 Years
- Healthy volunteers
- Accepted
Summary
Due to antigenic changes of influenza viruses, the virus strains used in influenza vaccines are adjusted every year according to WHO and CPMP recommendations. Immunogenicity and tolerability of the newly composed vaccines are subject for evaluation in a yearly clinical trial in non-elderly adults and elderly subjects (CPMP/BWP/214/96).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Surface antigen inactivated influenza vaccine | 1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2007-08-20
- Last updated
- 2016-12-01
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00518453. Inclusion in this directory is not an endorsement.